Story
GenFleet Initiates Phase III Trial for KRAS G12D Inhibitor in Lung Cancer

GenFleet Therapeutics (02595.HK) has initiated a Phase III registrational clinical trial in China for GFH375, its oral KRAS G12D inhibitor, as a treatment for non-small cell lung cancer (NSCLC), according to a company announcement. The enrollment of the first patient marks a key milestone, launching the second pivotal study for the drug candidate.
Trial Design and Scope
The study, named "Qilin-Fei 01," is a multi-center, open-label, randomized controlled trial that will evaluate the efficacy of GFH375 monotherapy compared to docetaxel. It is designed for patients with KRAS G12D-mutated, locally advanced unresectable or metastatic NSCLC who have not responded to standard treatment.
The trial is set to be conducted across more than 40 research centers in China. The first patient was recently enrolled at Nanjing Gulou Hospital, the company stated.
Expanding Clinical Program
This NSCLC trial is the second Phase III study for GFH375. The first, "Qilin-Yi 01," was initiated last year for pancreatic cancer and was reportedly the world's first pivotal trial for an oral KRAS G12D inhibitor in that indication.
AdEarlier this year, GFH375 received two Breakthrough Therapy Designations (BTD) in China for its potential as a monotherapy in both KRAS G12D-mutated NSCLC and pancreatic cancer, signaling regulatory recognition of its potential to address a significant unmet need.
Market Significance and Outlook
Currently, there are no approved targeted therapies for patients with the KRAS G12D mutation. This patient population often shows lower sensitivity to chemotherapy and a poor response rate to PD-1/L1 immunotherapy inhibitors, leaving them with limited effective treatment options after first-line therapy.
GenFleet noted that GFH375 has demonstrated potential best-in-class efficacy among KRAS G12D inhibitors in development globally. The company plans to present the latest data from its NSCLC monotherapy study in an oral report at the upcoming World Conference on Lung Cancer (WCLC), a key potential catalyst for investors.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.